A man and a woman hug in front of a meadow.


Professor Blanc is a member of the International Liver Cancer Association (ILCA), the French Association for Study of Liver Disease (AFEF) and the French Federation of Digestive Oncology (FFCD). Professor Blanc was the principal investigator in two clinical trials around best supportive care drug treatment of patients with hepatocellular carcinoma.



Dr. Finn is a Professor of Clinical Medicine in the Division of Hematology/Oncology. He currently splits his time between patient care and laboratory and clinical research. An active cancer researcher, he has been involved in the development of several novel therapeutics in cancer medicine. Dr. Finn is a member of the American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR) and the European Society of Medical Oncology (ESMO) and is a past president of ILCA.



Dr. Frenette is a gastroenterologist and medical director who has worked diligently to provide excellent medical care to patients with end stage liver disease and liver cancer. In addition to directing two major medical programs in Southern California, Dr. Frenette has been the Principle or Co-Investigator for multiple clinical trials related to liver disease and liver cancer. She also serves a key role in the training of gastroenterology fellows, as well as internal medicine residents.



Professor Galle is a member of several societies such as the American Association of the Study of Liver Diseases (AASLD) and the European Association for the Study of Liver (EASL). He was a member of the Executive Board and President of ILCA and is also President of the German Association for the Study of the Liver (GASL) for the year 2020. Professor Galle has served as co-editor for the Journal of Hepatology and was on the editorial boards of several other Journals. His research has focused on molecular aspects of hepatocellular carcinoma and chaired the panel updating the EASL Clinical Practice Guideline on HCC which appeared in 2018.



Dr. Kirhan Ozgurdal is the Global Medical Lead for Stivarga and Nexavar in HCC. He is a medical doctor by training and has been working at Bayer since 2010 where he previously held country and regional roles in oncology. He is currently the medical expert and scientific lead for several HCC clinical projects at Bayer.